One of the biggest mistakes pharmaceutical companies make is treating FDA inspection findings as isolated events. A Form 483 issued in Ireland is viewed as an Irish problem. A Warning Letter in India becomes an Indian manufacturer’s problem. A data integrity finding in China is dismissed as another example of regional quality challenges.
The FDA doesn’t see it that way.
Every foreign inspection contributes to a much larger picture of risk across the global pharmaceutical supply chain. Each inspection adds another data point that helps regulators determine where systemic weaknesses exist, how inspection resources should be allocated, and which organizations warrant closer scrutiny during future inspections. As the FDA continues rebuilding its foreign inspection program and increasingly relies on risk-based targeting, companies should spend less time asking, “Could this happen to us?” and more time asking, “What patterns are emerging that apply to all of us?” (Reed Smith)
One of the more interesting trends is the growing distinction between inspections conducted in Europe and those conducted throughout much of Asia. While the same GMP regulations apply regardless of geography, the nature of the observations often reflects differences in organizational maturity rather than differences in regulatory expectations.
Across many European facilities, FDA investigators are increasingly focusing on the effectiveness of mature quality systems rather than simply determining whether those systems exist. Documentation is generally complete, procedures are well established, and computerized systems are validated. Instead, inspections often probe deeper into management oversight, investigation quality, effectiveness of CAPA, contamination control strategies, supplier oversight, lifecycle process validation, and whether Quality Risk Management is truly driving business decisions or merely supporting compliance documentation.
In many respects, European inspections have become inspections of organizational judgment. Investigators frequently ask whether companies recognize emerging risks before they become deviations, whether trend data results in meaningful preventive actions, and whether senior leadership is actively engaged in maintaining a state of control. These inspections are less about checking boxes and more about determining whether quality systems consistently deliver the outcomes they were designed to achieve.
The inspection dynamic can be different at many facilities across Asia, although broad generalizations should always be avoided because the region contains some of the world’s highest-performing manufacturing sites alongside facilities still developing quality maturity. FDA observations have historically placed greater emphasis on foundational GMP execution, including data integrity, laboratory controls, documentation practices, batch record completeness, equipment maintenance, validation, and investigation quality. While these themes are certainly not unique to Asia, they continue to appear with greater frequency in inspection outcomes and enforcement actions involving manufacturers supplying global markets. (Pharmaceutical Online)
Perhaps the most persistent issue continues to be data integrity. Yet even here, many organizations misunderstand what regulators are actually communicating. FDA investigators are rarely suggesting that companies intentionally falsify records. Instead, they repeatedly identify weak governance surrounding electronic systems, inadequate audit trail review, shared user accounts, incomplete investigations, and a culture in which quality personnel are unable to consistently challenge questionable practices. These observations point to organizational weaknesses far more than technological failures.
Another trend becoming increasingly apparent is that FDA investigators are looking beyond the manufacturing floor. Modern inspections frequently evaluate the effectiveness of quality management systems as integrated business processes. Investigators want evidence that deviations lead to meaningful investigations, investigations drive effective CAPAs, CAPAs reduce recurring events, management reviews identify emerging risks, and metrics influence strategic decisions. In other words, they are evaluating whether the quality system functions as a living management system rather than a collection of disconnected procedures.
Companies should also recognize that FDA inspections no longer occur in isolation. The Agency has access to inspection histories, application reviews, import data, adverse event information, previous enforcement actions, and intelligence gathered through international regulatory collaboration. A successful inspection today is influenced as much by the organization’s historical performance and demonstrated quality culture as by what investigators observe during the week they are on-site. Increasingly, inspection planning and follow-up activities are becoming more data-driven and risk-based. (Reed Smith)
There is another nuance that deserves attention. European manufacturers often assume their history of successful inspections by European regulators will naturally translate into FDA success. Likewise, many Asian manufacturers focus heavily on correcting individual FDA observations without addressing the broader management systems that allowed those issues to develop. Both approaches miss the point. FDA investigators are remarkably consistent in looking for evidence that organizations understand their own risks before the Agency identifies them.
That distinction separates companies that merely pass inspections from companies that operate in a sustained state of inspection readiness. The former prepare extensively in the months leading up to an inspection. The latter continuously evaluate the health of their quality systems, challenge assumptions, monitor leading indicators, and strengthen governance before compliance gaps emerge.
As FDA resumes a more robust foreign inspection program and continues refining its risk-based inspection strategy, organizations should expect inspections to become increasingly sophisticated rather than simply more frequent. Investigators are spending less time determining whether procedures exist and more time evaluating whether those procedures actually prevent quality failures. That represents an important evolution in regulatory oversight and one that every global manufacturer should recognize.
Ultimately, the geography of an inspection matters far less than the maturity of the organization being inspected. Whether a facility operates in Dublin, Basel, Hyderabad, Shanghai, Singapore, or Tokyo, the FDA is asking the same fundamental question: Can this organization consistently demonstrate that it understands its risks, controls its processes, learns from its mistakes, and protects patients?
At Quality Executive Partners, we believe the strongest inspection strategy is not preparing for the next FDA visit—it is building quality systems mature enough that inspections become a confirmation of operational excellence rather than a test of compliance. Through our experienced consultants, proven remediation methodologies, and Virtuosi immersive workforce development platform, we help organizations strengthen the governance, quality culture, and operational discipline necessary to succeed under increasing global regulatory scrutiny.
QxP Vice President Christine Feaster is a 20+ year veteran in pharma quality assurance. Prior to joining QxP, Christine was a vice president of U.S. Pharmacopeia.
